Acute Rejection of Renal Transplant
9
1
2
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
33%
3 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection
Donor-derived Cell-free DNA in Kidney Transplant Recipients
Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant
Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections
The Effects of Pre-transplant Dialysis Modality on Post-transplant Events
European Transplant Registry of Senior Renal Transplant Recipients on Advagraf
Intensified Dosing of Cellcept (Mycophenolate Mofetil) in Kidney Transplantation
Study to Evaluate Safety and Immunologic Biomarker of Rapamune in Patients With Stable Renal Transplant Recipient
Reasons for Mycophenolate Mofetil Dose Reduction and Impact on Graft Outcome in Renal Transplant Recipients